# plaque psoriasis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/plaque-psoriasis

> 16 upcoming FDA catalysts in plaque psoriasis: ORKA-002 (ORKA) on October 2027 (primary completion); ORKA-002 (ORKA) on Oct 2027 to Jan 2028 (topline data readout); envudeucitinib (ALMS) on December 2027 (primary completion); envudeucitinib (ALMS) on Dec 2027 to Mar 2028 (topline data readout); and 12 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 5, 2023 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT | plaque psoriasis | completed, approved | "NDA215985 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20231005, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| September 19, 2025 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | completed | "NCT06586112 (A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06586112)) |
| September 23, 2025 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | completed | "NCT06588738 (A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588738)) |
| November 17, 2025 | [WEZLANA® (ustekinumab) primary completion](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Plaque Psoriasis | completed | "NCT06934226 (A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-17 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06934226)) |
| November 20, 2025 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | completed | "NCT05565560 (A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05565560)) |
| December 16, 2025 | [Zl-1102 1% w/w gel bid for 16 weeks primary completion](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) | ZLAB | Plaque Psoriasis | withdrawn | "NCT06380907 (A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Zai Lab (Hong Kong), Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06380907)) |
| March 25, 2026 | [Orka-001 induction dose primary completion](https://sec-api.dev/pdufa/orka-001-induction-dose) | ORKA | Plaque Psoriasis | completed | "NCT07090330 (ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07090330)) |
| April 22, 2026 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Plaque Psoriasis | completed | "NCT06973291 (A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973291)) |
| August 12, 2026 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | completed | "NCT06088199 (A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06088199)) |
| Aug to Nov 2026 | [Otezla (apremilast) topline data readout](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | scheduled | "NCT06088199 (A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06088199)) |
| October 14, 2026 | [Tapinarof cream, 1% primary completion](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Plaque Psoriasis | completed | "NCT05172726 (Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-14 (ACTUAL); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172726)) |
| Oct 2026 to Jan 2027 | [Tapinarof cream, 1% topline data readout](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Plaque Psoriasis | scheduled | "NCT05172726 (Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-14 (ACTUAL); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172726)) |
| October 21, 2026 | [ORKA-001 primary completion](https://sec-api.dev/pdufa/orka-001) | ORKA | Plaque Psoriasis | completed | "NCT07290569 (Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07290569)) |
| Oct 2026 to Jan 2027 | [ORKA-001 topline data readout](https://sec-api.dev/pdufa/orka-001) | ORKA | Plaque Psoriasis | scheduled | "NCT07290569 (Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07290569)) |
| October 2027 | [ORKA-002 primary completion](https://sec-api.dev/pdufa/orka-002) | ORKA | Plaque Psoriasis | scheduled | "NCT07474792 (Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07474792)) |
| Oct 2027 to Jan 2028 | [ORKA-002 topline data readout](https://sec-api.dev/pdufa/orka-002) | ORKA | Plaque Psoriasis | scheduled | "NCT07474792 (Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07474792)) |
| December 2027 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | scheduled | "NCT05739435 (Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05739435)) |
| Dec 2027 to Mar 2028 | [Envudeucitinib topline data readout](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | scheduled | "NCT05739435 (Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05739435)) |
| December 2027 | [Piclidenoson primary completion](https://sec-api.dev/pdufa/piclidenoson) | CANF | Plaque Psoriasis | scheduled | "NCT06643260 (A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643260)) |
| Dec 2027 to Mar 2028 | [Piclidenoson topline data readout](https://sec-api.dev/pdufa/piclidenoson) | CANF | Plaque Psoriasis | scheduled | "NCT06643260 (A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643260)) |
| January 2029 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04772079)) |
| Jan to Apr 2029 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04772079)) |
| July 2029 | [ORKA-002 primary completion](https://sec-api.dev/pdufa/orka-002) | ORKA | Plaque Psoriasis | scheduled | "NCT07933783 (An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07-01 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07933783)) |
| Jul to Oct 2029 | [ORKA-002 topline data readout](https://sec-api.dev/pdufa/orka-002) | ORKA | Plaque Psoriasis | scheduled | "NCT07933783 (An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07-01 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07933783)) |
| Aug to Nov 2029 | [TAK-279 topline data readout](https://sec-api.dev/pdufa/tak-279) | TAK | Plaque Psoriasis | scheduled | "NCT06550076 (A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550076)) |
| August 2029 | [TAK-279 primary completion](https://sec-api.dev/pdufa/tak-279) | TAK | Plaque Psoriasis | scheduled | "NCT06550076 (A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550076)) |
| Oct 2029 to Jan 2030 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT06979453 (A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-12 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979453)) |
| October 2029 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT06979453 (A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-12 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979453)) |
| May 2030 | [ORKA-001 primary completion](https://sec-api.dev/pdufa/orka-001) | ORKA | Plaque Psoriasis | scheduled | "NCT07449702 (An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07449702)) |
| May to Aug 2030 | [ORKA-001 topline data readout](https://sec-api.dev/pdufa/orka-001) | ORKA | Plaque Psoriasis | scheduled | "NCT07449702 (An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07449702)) |

## Drugs

- [ZORYVE (roflumilast)](https://sec-api.dev/pdufa/roflumilast) (ARQT)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [TAK-279](https://sec-api.dev/pdufa/tak-279) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/plaque-psoriasis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "plaque psoriasis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/plaque-psoriasis

```bibtex
@misc{secapidev_indications_plaque_psoriasis_20261116,
  title        = {plaque psoriasis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/plaque-psoriasis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_plaque_psoriasis_20261116","title":"plaque psoriasis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/plaque-psoriasis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
